Claims:

1. A double-stranded nucleic acid molecule comprising a sense strand and an antisense strand, wherein the sense strand and the antisense strand are selected from the oligonucleotides described as RHOA_48 (SEQ ID NOS: 79 and 113) or the oligonucleotides described as RHOA_48u (SEQ ID NOS: 80 and 114); or a pharmaceutically acceptable salt of such nucleic acid molecule;

wherein the double stranded nucleic acid molecule is a siRNA; and

wherein the double-stranded nucleic acid molecule has the structure:

```
5′    UGUAGCAAGAUGACUUCUG -Z  3′ (antisense SEQ ID NO:113)
      ||||||||||||||||||
3′ Z′-ACAUCGUUCUACUGAAGAC -z″ 5′ (sense SEQ ID NO:79)
```

or

```
5′    AGUAGCAAGAUGACUUCUG -Z  3′ (antisense SEQ ID NO:114)
      ||||||||||||||||||
3′ Z′-UCAUCGUUCUACUGAAGAC -z″ 5′ (sense SEQ ID NO:80)
```

wherein each "|" represents base pairing;

wherein each of A, C, G and U is independently an unmodified ribonucleotide, a modified ribonucleotide, or an unconventional moiety;

wherein said unconventional moiety is selected from a mirror nucleotide and a nucleotide joined to an adjacent nucleotide by a 2′-5′ internucleotide phosphate bond;

wherein each of Z and Z′ is independently 1-5 consecutive nucleotides or non-nucleotide moieties or a combination thereof covalently attached at the 3′ terminus of the strand in which it is present;

wherein z″ is a capping moiety covalently attached at the 5′ terminus of the sense strand.

Optic Neuropathy (AION), Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), Arteritic Anterior Ischemic Optic Neuropathy (AAION), neuropathic pain (NP), allodynia, cancer, tumor growth; and a proliferative disease.

20. The use of claim 19, wherein the injury is a spinal cord injury.

21. The use of claim 19, wherein the disorder is neuropathic pain (NP) or allodynia.

22. A double-stranded nucleic acid molecule comprising a sense strand and an antisense strand, wherein the sense strand and the antisense strand are selected from an oligonucleotide described as RHOA 48 (SEQ ID NOS: 79 and 113) or RHOA 48u (SEQ ID NOS: 80 and 114), wherein said molecule is a siRNA; or a pharmaceutically acceptable salt of such nucleic acid molecule.